In this edition of The Upside, Lou Basenese sits down with Dan Schmitt, CEO of Actuate Therapeutics, the biotech behind a potential breakthrough in one of the deadliest cancers. Actuate’s lead drug, elraglusib, doubled one-year survival when added to standard chemo. After treating more than 500 patients, the data points to a true “pipeline in a molecule” with applications far beyond pancreatic cancer. Schmitt explains why upcoming regulatory milestones could be transformative – and why the market still hasn’t priced in the company’s multi-billion-dollar opportunity.